Data Insights

AM-003 by Aummune Therapeutics for Metastatic Colorectal Cancer: Likelihood of Approval

AM-003 is under clinical development by Aummune Therapeutics and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AM-003 in Metastatic Colorectal Cancer

Data Insights

AM-003 by Aummune Therapeutics for Soft Tissue Sarcoma: Likelihood of Approval

AM-003 is under clinical development by Aummune Therapeutics and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AM-003 in Soft Tissue Sarcoma

Data Insights

AM-003 by Aummune Therapeutics for Thyroid Cancer: Likelihood of Approval

AM-003 is under clinical development by Aummune Therapeutics and currently in Phase I for Thyroid Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AM-003 in Thyroid Cancer

Data Insights

AM-003 by Aummune Therapeutics for Nonmelanomatous Skin Cancer: Likelihood of Approval

AM-003 is under clinical development by Aummune Therapeutics and currently in Phase I for Nonmelanomatous Skin Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AM-003 in Nonmelanomatous Skin Cancer

Data Insights

AM-003 by Aummune Therapeutics for Metastatic Melanoma: Likelihood of Approval

AM-003 is under clinical development by Aummune Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AM-003 in Metastatic Melanoma

Data Insights

AM-003 by Aummune Therapeutics for Solid Tumor: Likelihood of Approval

AM-003 is under clinical development by Aummune Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AM-003 in Solid Tumor

Data Insights

AM-003 by Aummune Therapeutics for Head And Neck Cancer: Likelihood of Approval

AM-003 is under clinical development by Aummune Therapeutics and currently in Phase I for Head And Neck Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - AM-003 in Head And Neck Cancer